Hagens Berman said it is investigating claims in a securities class action against Erasca, Inc. over alleged misstatements about lead oncology candidate ERAS-0015 during the Jan. 14, 2025 to Apr. 26, 2026 class period. Court filings and law firm releases allege Erasca promoted ERAS-0015 as a best-in-class pan-RAS molecular glue using improper cross-study comparisons with Revolution Medicines' RMC-6236, failed to disclose exposure to patent infringement and trade secret misappropriation claims, and downplayed safety risks. The complaint points to an Apr. 27, 2026 Form 8-K disclosing a letter from Revolution Medicines' counsel alleging infringement of U.S. Patent No. 12,409,225, alleged trade secret misappropriation, and deceptive comparative statements; Erasca said it believed the claims were without merit and would contest them. Hagens Berman also said disclosures on Apr. 27-28, 2026, including preliminary trial data that included a patient death linked to ERAS-0015, removed alleged artificial inflation from the stock, while one filing cited a drop from $21.49 on Apr. 24 to a $20.70 open and $19.15 close on Apr. 27. Investors seeking lead plaintiff status must act by Aug. 10, 2026.